Structuring, Negotiating and Managing

PHARMA/BIOTECH COLLABORATIVE AGREEMENTS

Tuesday, July 14, 2009

About

Meet the key dealmakers who will launch your company to the next level and provide the well-needed infusion of capital and products

2009 has ushered in a new paradigm for Pharma/Biotech deal structuring. The current economic climate has altered both the approach and management of collaborative agreements and companies are now struggling to quickly adapt. For Pharma and Biotech companies to survive and thrive, it has become more essential than ever to not only cultivate relationships with the key industry players, but also to maximize the value of the deal and protect your assets by incorporating the evolving trends into current and future agreements.

Based on extensive research with industry professionals, ACI’s Advanced Forum on Structuring, Negotiating, and Managing Pharma/Biotech Collaborative Agreements was designed to provide you with the most up to date strategic analysis of current deal structuring while also delivering outstanding networking and business development opportunities to ensure you walk away with the contacts and intelligence you need to forge successful new alliances.

An exceptional faculty of diverse speakers will show you how to develop and cultivate lucrative relationships by sharing strategies on and solutions for:

  • Capitalizing on shifting trends in the venture capital investment landscape
  • Drafting critical termination terms
  • Forging and protecting lucrative relationships with investors
  • Negotiating partnerships with start-up innovators and government programs
  • Contending with increased pressure from anxious investor’s seeking an immediate healthy return on their investment
  • Redefining alliance management priorities
  • Positioning your IP portfolio to increase your market power
  • Negotiating milestones into the compensation structure
  • Converting a licensing deal into an acquisition

 

Contents & Contributors

About

Meet the key dealmakers who will launch your company to the next level and provide the well-needed infusion of capital and products

2009 has ushered in a new paradigm for Pharma/Biotech deal structuring. The current economic climate has altered both the approach and management of collaborative agreements and companies are now struggling to quickly adapt. For Pharma and Biotech companies to survive and thrive, it has become more essential than ever to not only cultivate relationships with the key industry players, but also to maximize the value of the deal and protect your assets by incorporating the evolving trends into current and future agreements.

Based on extensive research with industry professionals, ACI’s Advanced Forum on Structuring, Negotiating, and Managing Pharma/Biotech Collaborative Agreements was designed to provide you with the most up to date strategic analysis of current deal structuring while also delivering outstanding networking and business development opportunities to ensure you walk away with the contacts and intelligence you need to forge successful new alliances.

An exceptional faculty of diverse speakers will show you how to develop and cultivate lucrative relationships by sharing strategies on and solutions for:

  • Capitalizing on shifting trends in the venture capital investment landscape
  • Drafting critical termination terms
  • Forging and protecting lucrative relationships with investors
  • Negotiating partnerships with start-up innovators and government programs
  • Contending with increased pressure from anxious investor’s seeking an immediate healthy return on their investment
  • Redefining alliance management priorities
  • Positioning your IP portfolio to increase your market power
  • Negotiating milestones into the compensation structure
  • Converting a licensing deal into an acquisition

 

Contents & Contributors

Predicting Future Trends & Developing Emerging Strategies in the Current Economic Environment
Yael Weiss, M.D., Ph.D., Director, Licensing and External Research, Merck and Co., Inc. (San Francisco, CA)
Anna Protopapas, Senior Vice President, Corporate Development and Strategy, Millennium, The Takeda Oncology Company (Cambridge, MA)
Kathleen Sereda Glaub, President, Plexxikon Inc. (Berkeley, CA)

Conducting Effective & Strategic Due Diligence
Mary Catherine DiNunzio, Head of Global Patent Alliances, H. Lundbeck A/S, (Copenhagen, Denmark)
Margaret M. Buck, MLS, JD, Patent Attorney, Lundbeck Research USA, Inc., (Paramus, NJ)
Jean Burke Fordis, Partner, Finnegan, Henderson, Farabow, Garrett & Dunner (Palo Alto, CA)
Stephen Johnson, Partner, Kirkland & Ellis LLP (San Francisco, CA)

Negotiating Essential Critical Terms to Maximize Profitability
Philip J. Honerkamp, Vice President, Deputy General Counsel, Jazz Pharmaceuticals Inc. (Palo Alto, CA)
James C. Snipes, Partner, Covington & Burling LLP (San Francisco, CA)
Jeffrey L. Wade, Executive Vice President and General Counsel, Lexicon Pharmaceuticals, Inc. (The Woodlands, TX)
Tanya Dobash Berlage, Partner and Chair, Life Sciences Practice Group, Saul Ewing LLP (Baltimore, MD)

Developing a Profitable Compensation Structure with Built-in Milestones to Maximize Value
Ron Myers, Vice President, Corporate Development and Legal Affairs, VLST Corp (Seattle, WA)
Cheni Kwok, Ph.D., CLP, Senior Vice President, Corporate Development, Poniard Pharmaceuticals (South San Francisco, CA)
Alex Scott, Vice President, Business Development, Eisai Inc. (Teaneck, NJ)

Structuring the Agreement with an Eye Towards M&A
Jeffrey C. Selman, Partner, Nixon Peabody LLP (Palo Alto, CA)

Creating and Implementing Critical Termination Provisions
Thomas E. Duley, Of Counsel, Morgan Lewis & Bockius LLP (San Francisco, CA)
(Former Senior Corporate Counsel and Head of Transactional Group for PDL BioPharma, Inc.)
Judith Ann Hasko, Partner, Latham & Watkins LLP (Menlo Park, CA)
Jonathan S. Dickstein, Partner, Morrison & Foerster LLP (San Francisco, CA)

Alliance Management: Establishing Governance Structures for Successful Collaborations
Mary Jo Struttmann, MBA, CA-AM, Senior Director, Alliance Management, Astellas US LLC (Deerfield, IL)
Andrew A. Paul, Senior Counsel, The Procter & Gamble Company, (Cincinnati, OH)

Crafting International Business Agreements for Calculated Growth and Sustainability
Stephen C. Ferruolo, Partner, Goodwin Procter LLP (San Diego, CA)
Maggie L. Wong, Associate, Goodwin Procter LLP (San Diego, CA)

Negotiating Collaborative Research Agreements with the U.S. Government and Academic Institutions
Claire T. Driscoll, Director, Technology Transfer Office, National Human Genome Research Institute (NHGRI), National Institutes of Health (NIH) (Bethesda, MD)
Brian Cummings, Executive Director, Technology Commercialization, University of Utah (Salt Lake City, UT)
David G. Schetter, Assistant Vice Chancellor for Research (Retired), University of California, Irvine (Irvine CA)
Bernadette M. Broccolo, Partner, McDermott Will & Emery, LLP (Chicago, IL)

Anticipating Future Technologies and Incorporating Terms into the Agreement to Protect Future Rights
Ralph A. Loren, Partner, Edwards Angell Palmer & Dodge, LLP (Boston, MA)



DOCUMENT TYPES: PPT DOC PDF PRESENTATIONS AVAILABLE: 19

8:00
Registration and Continental Breakfast
8:45
Co-Chairs' Opening Remarks
Mr. - Thomas Duley
Of Counsel
Morgan Lewis & Bockius LLP
Mr. James C. Snipes
Partner
Covington & Burling LLP
9:00
Predicting Future Trends & Developing Emerging Strategies in the Current Economic Environment
Yael Weiss, M.D.‚ J.D.
Director‚ Licensing and External Research
Merck and Co.‚ Inc.
1 file
Trends in Pharma - New Strategic Initiatives at Merck
6.3 MB 49 pages Presentation
PPT - Trends in Pharma - New Strategic Initiatives at Merck
Ms. Anna Protopapas
Senior Vice President‚ Corporate Development and Strategy
Millennium Pharmaceuticals‚ The Takeda Oncology Company
1 file
Predicting Future Trends & Developing Emerging Strategies in the Current Economic Environment
2 MB 20 pages Presentation
PPT - Predicting Future Trends & Developing Emerging Strategies in the Current Economic Environment
Ms. Kathleen Sereda Glaub
President
Plexxikon Inc.
1 file
Plexxikon Overview – July 2009 Building a New Drug Company
8.6 MB 10 pages Presentation
PPT - Plexxikon Overview – July 2009 Building a New Drug Company
10:20
Morning Refreshment Break
10:35
Conducting Effective & Strategic Due Diligence
Ms. Mary Catherine DiNunzio
Head of Global Patent Alliances
H. Lundbeck A/S
1 file
Example of an Intellectual Property Due Diligence List
28.5 KB 2 pages Presentation
DOC - Example of an Intellectual Property Due Diligence List
Ms. Margaret M. Buck
Patent Attorney
Lundbeck Research USA. Inc.
1 file
Intellectual Property Due Diligence: Why, When, Who, What & How Much?
722.5 KB 16 pages Presentation
PPT - Intellectual PropertyDue Diligence:Why, When, Who, What & How Much?
Jean Burke Fordis
Partner
Finnegan‚ Henderson‚ Farabow‚ Garrett & Dunner
1 file
Conducting Effective and Strategic Due Diligence: Dealing with the Documents
474.5 KB 31 pages Presentation
PPT - Conducting Effective and Strategic Due Diligence: Dealing with the Documents
Mr. Stephen Johnson
Partner
Kirkland & Ellis LLP
1 file
Conducting Effective and Strategic Due Diligence
273.5 KB 17 pages Presentation
PPT - Conducting Effective and Strategic Due Diligence
12:10
Networking Luncheon
13:25
Negotiating Essential Critical Terms to Maximize Profitability
Mr. Philip J. Honerkamp
Vice President‚ Deputy General Counsel
Jazz Pharmaceuticals‚ Inc.
Mr. James C. Snipes
Partner
Covington & Burling LLP
Mr. Jeffrey L. Wade
Executive Vice President and General Counsel
Lexicon Pharmaceuticals‚ Inc.
Ms. Tanya Berlage
Partner
Saul Ewing LLP
1 file
Negotiating Critical Terms to Maximize Profitability
341.5 KB 15 pages Presentation
PPT - Negotiating Critical Terms to Maximize Profitability
14:40
Afternoon Refreshment Break
14:50
Developing a Profitable Compensation Structure with Built-in Milestones to Maximize Value
Mr. Ron Myers
Vice President‚ Corporate Development and Legal Affairs
VLST‚ Corp.
1 file
VLST - Autoimmune & Inflammatory Therapeutics
1.6 MB 16 pages Presentation
PPT - VLST - Autoimmune & Inflammatory Therapeutics
Cheni Kwok, Ph.D.‚ CLP
Senior Vice President‚ Corporate Development
Poniard Pharmaceuticals‚ Inc.
1 file
Forward-Looking Statements
2.1 MB 14 pages Presentation
PPT - Forward-Looking Statements
Mr. Alex Scott
Vice President Business Development
Eisai Inc.
1 file
Developing a Profitable Compensation Structure
632.3 KB 15 pages Presentation
PDF - Developing a Profitable Compensation Structure
15:30
Structuring the Agreement with an Eye Towards M&A
Mr. Jeffrey C. Selman
Partner
Nixon Peabody LLP
1 file
Structuring the Agreement with an Eye Towards M&A
1.5 MB 47 pages Presentation
PPT - Structuring the Agreement with an Eye Towards M&A
Ms. Barbara A. Caulfield
Managing Partner
Dewey & LeBoeuf LLP
16:30
Networking Event
17:15
Conference Adjourns for the Day
9:00
Registration and Continental Breakfast
9:30
Co-Chairs' Remarks
Mr. - Thomas Duley
Of Counsel
Morgan Lewis & Bockius LLP
Mr. James C. Snipes
Partner
Covington & Burling LLP
9:40
Creating and Implementing Critical Termination Provisions
Mr. - Thomas Duley
Of Counsel
Morgan Lewis & Bockius LLP
Ms. Judith Ann Hasko
Partner
Latham & Watkins LLP
Mr. Jonathan S. Dickstein
Partner
Morrison & Foerster LLP
1 file
Creating and Implementing Critical Termination Provisions
253 KB 21 pages Presentation
PPT - Creating and Implementing Critical Termination Provisions
10:45
Morning Refreshment Break
11:00
Alliance Management: Establishing Governance Structures for Successful Collaborations
Ms. Mary Jo Struttmann
Senior Director‚ Alliance Management
Astellas US LLC
1 file
Alliance Management: Establishing Governance Structures for Successful Collaborations
4.4 MB 24 pages Presentation
PPT - Alliance Management: Establishing Governance Structures for Successful Collaborations
Andrew Paul
Senior Counsel
Procter & Gamble Company
1 file
Alliance Management: Getting the product to market, defending it, and resolving disputes
273 KB 20 pages Presentation
PPT - Alliance Management: Getting the product to market, defending it, and resolving disputes
13:15
Crafting International Business Agreements for Calculated Growth and Sustainability
Mr. Stephen C. Ferruolo
Partner
Goodwin Procter LLP
Ms. Maggie L. Wong
Associate
Goodwin Procter LLP
1 file
Crafting International Business Agreements for Calculated Growth and Sustainability
228.5 KB 24 pages Presentation
PPT - Crafting International Business Agreements for Calculated Growth and Sustainability
14:00
Afternoon Refreshment Break
14:15
Negotiating Collaborative Research Agreements with the U.S. Government and Academic Institutions
Ms. Claire T. Driscoll
Director‚ Technology Transfer Office
National Human Genome Research Institute‚ NIH
1 file
Government Labs are Different: NIH as a Research & Commercialization Partner
1.7 MB 25 pages Presentation
PPT - Government Labs are Different: NIH as a Research & Commercialization Partner
Mr. Brian Cummings
Executive Director‚ Technology Commercialization
University of Utah
Mr. David G. Schetter
Assistant Vice Chancellor for Research (Retired)
University of California‚ Irvine
Ms. Bernadette M. Broccolo
Partner
McDermott Will & Emery, LLP
1 file
Negotiating and Managing Collaborative Industry/University/Federal Agency Agreements
2.8 MB 51 pages Presentation
PPT - Negotiating and Managing Collaborative Industry/University/Federal Agency Agreements
15:00
Anticipating Future Technologies and Incorporating Terms into the Agreement to Protect Future Rights
Ralph A. Loren
Partner
Edwards Wildman Palmer LLP
1 file
ANTICIPATING FUTURE TECHNOLOGIES AND INCORPORATING TERMS INTO THE AGREEMENT TO PROTECT FUTURE RIGHTS
1.6 MB 20 pages Presentation
PPT - ANTICIPATING FUTURE TECHNOLOGIES AND INCORPORATING TERMS INTO THE AGREEMENT TO PROTECT FUTURE RIGHTS
16:15
Conference Concludes